parapsoriasis: one of a group of skin disorders that are characterized primarily by their resemblance to psoriasis (red, scaly lesions), rather than by their underlying etiology. Neoplasms can develop from parapsoriasis. For example, it can develop into cutaneous T-cell lymphoma.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
159 |
4. Check minimum number of eventsNone |
159 |
5. Include endpointsNone |
159 |
6. Filter based on genotype QC (FinnGen only) |
159 |
Control definitions (FinnGen only)
- Control exclude
- L12_PAPULOSQUAMOUS
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Other and unspecified parapsoriasis
based on the number of shared cases.
Similar with more cases:
- Parapsoriasis
- Papulosquamous disorders
- Diseases of the skin and subcutaneous tissue
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1163 | 429 | 723 |
| Only index persons | 1003 | 377 | 626 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.01 | 0.02 |
| Only index persons | 0.02 | 0.01 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 58.23 | 55.63 | 59.80 |
| Only index persons | 58.11 | 55.18 | 59.87 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 159 | 63 | 96 |
| Unadjusted period prevalence (%) | 0.03 | 0.02 | 0.04 |
| Median age at first event (years) | 56.27 | 56.68 | 55.99 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 141
- Matched controls
- 1411
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L41.9
ICD-10 Finland
Parapsoriasis, unspecified
+∞
93.4
79
*
L41.8
ICD-10 Finland
Other parapsoriasis
+∞
59.7
53
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
27.8
51.7
75
55
E0000UV
ATC
NA
9.7
33.5
103
307
D07AB08
ATC
desonide; topical
13.8
29.8
55
62
L30.9
ICD-10 Finland
Dermatitis, unspecified
9.4
28.3
69
130
D07AC01
ATC
betamethasone; topical
7.8
28.1
95
295
L40.0
ICD-10 Finland
Psoriasis vulgaris
286.5
24.4
24
*
E000001
ATC
NA
6.9
21.8
66
160
C84.0
ICD-10 Finland
Mycosis fungoides
+∞
21.4
20
*
L41.3
ICD-10 Finland
Small plaque parapsoriasis
+∞
21.4
20
*
E000002
ATC
NA
9.4
18.3
40
57
D07AC13
ATC
mometasone; topical
4.5
15.1
69
245
69621
ICD-8 Finland
Psoriasis and similar disorders, Parapsoriasis guttata
+∞
12.7
12
*
D07AB02
ATC
hydrocortisone butyrate; topical
4.0
12.0
60
221
D07AA02
ATC
hydrocortisone; topical
5.5
11.3
35
79
D02AX
ATC
Other emollients and protectives
23.7
10.9
15
7
D01AC20
ATC
imidazoles/triazoles in combination with corticosteroids; topical
3.7
10.2
52
190
D07AD01
ATC
clobetasol; topical
4.3
9.6
38
111
L41.4
ICD-10 Finland
Large plaque parapsoriasis
+∞
9.5
9
*
WXQ27
NOMESCO Finland
UVB narrow spectrum light therapy
26.0
9.1
12
5
E000003
ATC
NA
11.9
9.1
16
15
D05AX52
ATC
calcipotriol, combinations; topical
10.3
8.0
15
16
D07AC14
ATC
methylprednisolone aceponate; topical
8.7
7.3
15
19
D05BB02
ATC
acitretin; oral
21.3
7.2
10
5
E000007
ATC
NA
8.2
7.1
15
20
D02AE01
ATC
carbamide; topical
5.5
7.0
20
41
R21
ICD-10 Finland
Rash and other nonspecific skin eruption
8.8
6.5
13
16
L41.1
ICD-10 Finland
Pityriasis lichenoides chronica
+∞
6.3
6
*
9700/3-C44.5
ICD-O-3
Mycosis fungoides of skin of trunk
+∞
6.3
6
*
D05AX02
ATC
calcipotriol; topical
9.2
6.2
12
14
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
60
178
4.81
19.39
4.8
4.2
217.9
243.9
u/l
1.65
60
167
122
745
3.74
11.91
10.9
9.9
4.1
4.1
e9/l
0.10
116
654
10
5
21.19
7.23
1.4
1.6
—
—
—
0
0
18
54
3.63
5.35
1.6
2.0
0.6
0.6
g/l
0.03
18
48
18
61
3.20
4.45
1.5
1.9
—
—
—
0
0
76
503
1.98
4.27
2.4
2.2
75.2
76.9
nmol/l
0.21
71
438
16
53
3.24
4.09
1.5
2.0
36.8
36.3
g/l
0.11
16
45
43
254
1.95
3.23
4.6
3.2
2.5
2.5
mmol/l
0.22
37
222
5
5
10.26
3.00
2.8
1.4
581.8
1014.4
u/ml
—
5
5
20
94
2.29
2.68
4.0
4.2
90.8
88.1
ng/l
0.06
20
81
33
189
1.94
2.68
16.5
5.5
103.3
103.9
mmol/l
0.31
33
183
140
1240
2.08
2.38
22.1
15.2
75.7
76.2
ml/min/173m2
0.10
129
1006
64
462
1.64
2.35
3.1
3.2
1442.5
1228.8
ng/l
0.29
56
393
62
445
1.64
2.33
4.7
3.7
2.3
2.3
mmol/l
0.26
56
393
52
360
1.66
2.23
3.1
3.0
359.9
7871.9
umol/l
1.69
45
298
56
397
1.63
2.18
4.1
3.2
0.2
0.7
e6/l
1.59
47
294
67
501
1.58
2.08
4.0
3.3
—
—
—
0
0
73
557
1.57
2.08
2.5
1.9
93.9
94.4
pmol/l
0.03
46
285
19
99
2.04
2.00
1.7
1.7
—
—
—
0
0
84
670
1.54
1.92
10.6
6.6
1.2
1.2
mmol/l
1.17
72
559
110
936
1.57
1.84
4.4
3.7
15.4
14.9
pmol/l
1.21
102
832
19
103
1.96
1.81
2.3
3.2
58.3
61.2
ml/min/173m2
—
6
44
21
118
1.90
1.81
3.8
3.2
4.9
4.4
kpa
0.51
21
112
82
657
1.51
1.80
5.9
5.1
0.0
0.0
estimate
0.00
17
132
34
222
1.68
1.79
3.5
2.0
29.0
29.3
s
0.16
34
216
83
669
1.50
1.76
4.0
3.7
0.0
0.0
estimate
0.00
17
120
38
258
1.62
1.73
4.1
3.6
395.8
296.7
ng/l
0.13
31
217
36
242
1.63
1.70
3.1
2.7
0.9
1.0
e6/l
0.02
25
129
148
1371
2.15
1.69
27.5
19.3
83.8
83.2
umol/l
0.07
148
1371
34
226
1.64
1.68
3.3
2.9
2.3
2.1
e6/l
0.04
24
115
81
655
1.48
1.66
4.0
3.7
0.0
0.0
estimate
0.00
17
132
12
57
2.20
1.59
1.3
1.3
—
—
—
0
0
131
1177
1.64
1.58
5.2
4.5
1.9
2.0
mu/l
0.52
121
1048
23
141
1.74
1.52
4.7
4.1
5.8
5.7
kpa
0.26
23
136
6
22
2.79
1.45
8.2
4.2
—
—
—
0
0
9
40
2.32
1.42
1.2
1.2
—
—
—
0
0
9
40
2.32
1.42
1.2
1.2
—
—
—
0
0
20
120
1.76
1.42
2.2
2.5
28.3
32.2
u/l
0.36
14
97
7
29
2.48
1.41
1.1
1.1
—
—
—
0
0
7
29
2.48
1.41
2.7
1.5
—
—
—
0
0
7
29
2.48
1.41
2.7
1.5
—
—
—
0
0
140
1290
1.71
1.39
4.8
4.9
1.4
1.4
mmol/l
0.40
128
1174
86
724
1.41
1.32
6.9
7.2
12.2
12.0
umol/l
0.06
80
683
140
1295
1.68
1.30
5.0
4.9
4.5
4.5
mmol/l
0.36
131
1193
14
77
1.90
1.30
3.4
2.9
1.0
1.1
%
0.13
14
77
31
216
1.54
1.26
1.3
1.3
20.9
40.2
iu/ml
—
9
72
6
26
2.36
1.20
1.2
1.5
—
—
—
0
0
139
1290
1.62
1.19
24.2
16.3
24.4
24.3
mg/l
0.02
117
1040
31
220
1.51
1.17
2.6
2.0
—
—
—
0
0
136
1260
1.55
1.12
4.4
4.3
1.3
1.3
mmol/l
0.08
124
1140
24
162
1.57
1.12
2.8
1.8
—
—
—
0
0
28
196
1.52
1.12
1.2
1.3
24.2
19.6
u/ml
0.12
14
67
35
258
1.46
1.10
1.4
1.2
0.9
1.2
u/ml
—
9
76
12
67
1.86
1.08
7.0
4.2
24.5
24.0
mmol/l
0.21
12
60
24
164
1.55
1.07
2.8
1.9
—
—
—
0
0
135
1254
1.51
1.04
6.1
6.4
39.9
41.0
mmol/mol
0.81
129
1163
7
34
2.11
1.04
1.0
1.2
—
—
—
0
0
141
1328
1.55
0.94
5.6
5.4
2.6
2.7
mmol/l
0.36
132
1212
6
32
1.91
0.82
1.0
1.4
—
—
—
0
0
36
287
1.33
0.72
2.8
1.7
1.2
1.4
mg/l
0.37
28
231
45
372
1.29
0.70
3.3
3.2
0.5
0.8
ug/l
3.21
26
251
17
119
1.48
0.70
23.8
5.3
1.2
1.3
mmol/l
0.14
17
114
10
61
1.68
0.70
1.0
1.0
—
—
—
0
0
7
43
1.66
0.67
3.6
2.2
21.9
24.5
mmol/l
—
7
38
77
684
1.24
0.66
2.4
2.5
—
—
—
0
0
13
87
1.54
0.65
2.0
1.4
—
—
—
0
0
11
72
1.57
0.61
2.3
1.8
—
—
—
0
0
20
150
1.38
0.59
2.8
3.8
—
—
—
0
0
0
23
0.00
0.59
0.0
3.5
—
34.0
—
0
7
43
362
1.26
0.58
1.9
1.6
1.6
1.3
mmol/l
0.67
36
292
134
1276
1.32
0.58
4.6
5.1
6.0
6.1
mmol/l
0.20
124
1159
120
1131
1.25
0.54
30.5
16.8
39.5
39.7
%
0.09
82
781
65
581
1.20
0.50
4.6
4.2
50.4
43.0
ng/l
0.14
45
443
58
516
1.20
0.46
4.5
4.7
21.2
21.5
%
0.04
23
258
9
127
0.69
0.45
1.3
1.3
—
—
—
0
0
5
32
1.58
0.42
1.8
1.4
—
0.0
—
0
7
0
16
0.00
0.41
0.0
2.0
—
—
—
0
0
0
16
0.00
0.41
0.0
2.0
—
—
—
0
0
0
18
0.00
0.40
0.0
1.9
—
—
—
0
0
5
36
1.40
0.38
2.4
1.8
—
—
—
0
0
40
352
1.18
0.36
4.2
3.9
0.0
0.0
estimate
0.00
17
127
65
599
1.14
0.32
6.5
4.1
—
—
—
0
0
7
53
1.34
0.31
3.1
2.8
—
—
—
0
0
69
642
1.13
0.29
6.0
5.3
2.0
2.8
ug/l
0.62
59
574
56
516
1.13
0.27
4.5
3.9
—
—
—
0
0
5
37
1.36
0.24
1.4
1.7
—
—
—
0
0
34
306
1.14
0.23
5.5
2.3
—
—
—
0
0
5
42
1.20
0.21
2.2
1.6
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
12
0.00
0.21
0.0
2.3
—
—
—
0
0
15
176
0.84
0.21
25.7
5.7
1.4
1.1
mmol/l
0.11
15
139
6
52
1.16
0.19
5.2
2.3
864.7
1229.5
ug/l
—
6
45
8
72
1.12
0.16
46.6
4.4
27.6
24.5
mmol/l
—
8
72
11
93
1.20
0.15
4.6
4.1
4.8
5.1
kpa
0.56
11
88
15
167
0.89
0.11
8.3
7.6
—
—
—
0
0
5
44
1.14
0.10
2.2
1.9
—
—
—
0
0
6
54
1.12
0.09
1.2
3.8
—
3.5
—
0
7
6
70
0.85
0.08
2.8
3.5
89.0
733.6
u/ml
—
6
56
16
173
0.92
0.07
24.1
5.6
10.6
11.6
kpa
1.06
16
167
16
173
0.92
0.07
24.3
5.6
5.1
5.0
kpa
0.08
16
167
14
128
1.10
0.07
1.4
2.2
13.0
13.0
nmol/l
0.01
14
117
45
435
1.05
0.06
3.9
3.6
33.5
36.0
u/l
0.22
45
408
87
856
1.04
0.05
3.2
3.4
50.7
54.7
u/l
0.19
82
794
45
437
1.04
0.05
2.3
2.7
75.9
57.2
u/l
0.33
40
405
31
300
1.04
0.03
1.8
1.9
453.4
440.5
pmol/l
0.10
24
249
28
271
1.04
0.03
1.8
1.7
1027.1
1239.6
nmol/l
0.83
21
205
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
2.8
—
13.6
—
0
6
0
9
0.00
0.00
0.0
4.3
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
2.2
—
—
—
0
0
0
6
0.00
0.00
0.0
2.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
4.3
—
—
—
0
0
0
6
0.00
0.00
0.0
2.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.9
—
—
—
0
0
0
9
0.00
0.00
0.0
4.3
—
69.1
—
0
9
9
98
0.91
0.00
1.6
1.9
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
16.4
—
0
5
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
16
160
1.00
0.00
1.6
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
0.00
0.0
1.9
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint L12_PARAPSO_RETIFORM and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_PARAPSO_RETIFORM | 1.069 [0.8, 1.43] | 0.653 |
| Birth year | 0.993 [0.98, 1.0] | 0.156 |
During the follow-up period (1.1.1998 — 31.12.2019), 59 out of 274 females with L12_PARAPSO_RETIFORM died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_PARAPSO_RETIFORM | 0.92 [0.76, 1.11] | 0.388 |
| Birth year | 0.985 [0.98, 0.99] | 0.003 |
During the follow-up period (1.1.1998 — 31.12.2019), 139 out of 529 males with L12_PARAPSO_RETIFORM died.
Mortality risk
Mortality risk for people of age
years, who have L12_PARAPSO_RETIFORM.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.084% | 0.16% |
| 5 | 0.627% | 0.949% |
| 10 | 1.432% | 2.37% |
| 15 | 2.799% | 4.725% |
| 20 | 5.179% | 8.278% |
Relationships between endpoints
↥Index endpoint: L12_PARAPSO_RETIFORM – Other and unspecified parapsoriasis
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data